Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Nusayba A Bagegni, Andrew A Davis, Katherine K Clifton & Foluso O Ademuyiwa. (2022) Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. Breast Cancer: Targets and Therapy 14, pages 113-123.
Read now
Read now
Frederick M. Howard, Dario Villamar, Gong He, Alexander T. Pearson & Rita Nanda. (2022) The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opinion on Investigational Drugs 31:6, pages 531-548.
Read now
Read now
Hikmat Abdel-Razeq, Faris Tamimi, Lama Abujamous, Sara Edaily, Mahmoud Abunasser, Rayan Bater & Osama Salama. (2021) Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives. Cancer Management and Research 13, pages 4597-4604.
Read now
Read now
Tara Hyder, Saveri Bhattacharya, Kristine Gade, Azadeh Nasrazadani & Adam M Brufsky. (2021) Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer. Breast Cancer: Targets and Therapy 13, pages 199-211.
Read now
Read now
Sun Young Oh, Shafia Rahman & Joseph A. Sparano. (2021) Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. Expert Opinion on Pharmacotherapy 22:8, pages 981-1003.
Read now
Read now
Articles from other publishers (28)
Ana Julia Aguiar Freitas, Caroline Rocha Nunes, Max Senna Mano, Rhafaela Lima Causin, Iara Viana Vidigal Santana, Marco Antonio de Oliveira, Stéphanie Calfa, Henrique César Santejo Silveira, Cristiano de Pádua Souza & Márcia Maria Chiquitelli Marques. (2023) Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial. Scientific Reports 13:1.
Crossref
Crossref
Bi Meng, Xuan Zhao, Shuchang Jiang, Zijian Xu, Sijin Li, Xu Wang, Wen Ma, Liantao Li, Dan Liu, Junnian Zheng, Hui Peng & Ming Shi. (2023) AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses. Frontiers in Immunology 14.
Crossref
Crossref
Li Yang, Weigang Zhang & Yifeng Yan. (2023) Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma. Aging 15:13, pages 6135-6151.
Crossref
Crossref
Cornelia Tolg, Maja Milojevic, Freda W. Qi, Hailie A. Pavanel, M. Elizabeth O. Locke, Jenny Ma, Mathew Price, Andrew C. Nelson, James B. McCarthy, Kathleen A. Hill & Eva A. Turley. (2023) RHAMM regulates MMTV-PyMT-induced lung metastasis by connecting STING-dependent DNA damage sensing to interferon/STAT1 pro-apoptosis signaling. Breast Cancer Research 25:1.
Crossref
Crossref
Brahim El Hejjioui, Salma Lamrabet, Sarah Amrani Joutei, Nadia Senhaji, Touria Bouhafa, Moulay Abdelilah Malhouf, Sanae Bennis & Laila Bouguenouch. (2023) New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer. Diagnostics 13:11, pages 1949.
Crossref
Crossref
Meghavi Kathpalia, Anurag Sharma & Navkiran Kaur. (2023) Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis. Annals of Pharmacotherapy, pages 106002802311641.
Crossref
Crossref
Kristen Jogerst, Chi Zhang, Yu-Hui Chang, Sami Abujbarah, Mariam Ali-Mucheru, Barbara Pockaj, Chee-Chee Stucky, Patricia Cronin & Nabil Wasif. (2023) Socioeconomic and racial disparities in survival for patients with stage IV cancer. The American Journal of Surgery.
Crossref
Crossref
Ombretta Melaiu, Gianluca Vanni, Ilaria Portarena, Chiara Adriana Pistolese, Lucia Anemona, Silvia Pomella, Roberto Bei, Oreste Claudio Buonomo, Mario Roselli, Alessandro Mauriello & Giovanni Barillari. (2023) The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. International Journal of Molecular Sciences 24:4, pages 3226.
Crossref
Crossref
David Terrero, Anil Shanker, Amit K. Tiwari & Dayanidhi Raman. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
20
.
Xingyu Chen, Lixiang Feng, Yujing Huang, Yi Wu & Na Xie. (2022) Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer. Cancers 15:1, pages 104.
Crossref
Crossref
Linlin Zhang, Shasha Guan, Fanlu Meng, Lin Teng & Diansheng Zhong. (2022) Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer. Frontiers in Oncology 12.
Crossref
Crossref
Giovanna Garufi, Luisa Carbognin, Francesco Schettini, Elia Seguí, Alba Di Leone, Antonio Franco, Ida Paris, Giovanni Scambia, Giampaolo Tortora & Alessandra Fabi. (2022) Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. Cancers 14:17, pages 4064.
Crossref
Crossref
Jun-Yan Liu, Ting Zou, Ji-Ye Yin, Zhan Wang, Chong Liu, Han-Xue Huang, Fei-Xiang Ding, Meng-Rong Lei, Ying Wang, Min Liu, Zhao-Qian Liu, Li-Ming Tan & Juan Chen. (2022) Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients With Lung Cancer. Frontiers in Pharmacology 13.
Crossref
Crossref
Xiaoyu Zhang, Huixin Li, Feng Wu, Dan Sun, Hengle Zhang, Lijun Jin, Xiaoning Kang & Zunyi Wang. (2022) Neoadjuvant Chemotherapy Combined with Breast-Conserving Surgery in the Treatment of Triple-Negative Breast Cancer. Journal of Oncology 2022, pages 1-6.
Crossref
Crossref
Yan Xiao & Wencheng Gao. (2022) Therapeutic pattern and progress of neoadjuvant treatment for triple‑negative breast cancer (Review). Oncology Letters 24:1.
Crossref
Crossref
Guillermo Arturo Valencia, Patricia Rioja, Zaida Morante, Rossana Ruiz, Hugo Fuentes, Carlos A Castaneda, Tatiana Vidaurre, Silvia Neciosup & Henry L Gomez. (2022) Immunotherapy in triple-negative breast cancer: A literature review and new advances. World Journal of Clinical Oncology 13:3, pages 219-236.
Crossref
Crossref
Fan Yang, Kaige Deng, Haoran Zheng, Zhenting Liu & Yongchang Zheng. (2022) Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing. Annals of Hepatology 27:2, pages 100677.
Crossref
Crossref
James D. Hampton, Erica J. Peterson, Samantha J. Katner, Tia H. Turner, Mohammad A. Alzubi, J. Chuck Harrell, Mikhail G. Dozmorov, Joseph B. McGee Turner, Pam J. Gigliotti, Vita Kraskauskiene, Mayuri Shende, Michael O. Idowu, Madhavi Puchalapalli, Bin Hu, Larisa Litovchick, Eriko Katsuta, Kazuaki Takabe, Nicholas P. Farrell & Jennifer E. Koblinski. (2022) Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics 21:2, pages 271-281.
Crossref
Crossref
Rama Rao Malla & Priyamvada Bhamidipati. (2022) γδ T Cell-Mediated Immune Responses for Cancer Therapy: Special Focus on Breast Cancer. Critical Reviews in Immunology 42:6, pages 9-15.
Crossref
Crossref
Zhang Wei, Fei Sijia, Tong Rui, Liu Yang, He Jianjun, Wan Bin & Xu Jing. (2021) Analysis of differentially expressed proteins between HER2 positive and triple negative breast cancer and their prognostic significance. Annals of Diagnostic Pathology 55, pages 151834.
Crossref
Crossref
S. V. Rykov, E. A. Filippova, V. I. Loginov & E. A. Braga. (2021) Gene Methylation in Circulating Cell-Free DNA from the Blood Plasma as Prognostic and Predictive Factor in Breast Cancer. Russian Journal of Genetics 57:11, pages 1239-1252.
Crossref
Crossref
Xu Han, Na Zhao, Wenwen Zhu, Jia Wang, Beixing Liu & Yuee Teng. (2021) Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmonary T cells and converting macrophages to M1 phenotype in a murine tumor model. Cellular Immunology 368, pages 104423.
Crossref
Crossref
Sebastián Omar Siri, Julieta Martino & Vanesa Gottifredi. (2021) Structural Chromosome Instability: Types, Origins, Consequences, and Therapeutic Opportunities. Cancers 13:12, pages 3056.
Crossref
Crossref
Jiannan Liu, Shuhua Wang, Congcong Wang, Xiangshuo Kong & Ping Sun. (2021) Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple‑negative breast cancer following neoadjuvant chemotherapy. Experimental and Therapeutic Medicine 21:3.
Crossref
Crossref
Lily Yu, Xiuhua Liu & Xiaochun Yu. (2021) ADP-ribosylhydrolases: from DNA damage repair to COVID-19ADP-核糖基水解酶:从DNA损伤修复到2019新型冠状病毒肺炎. Journal of Zhejiang University-SCIENCE B 22:1, pages 21-30.
Crossref
Crossref
Zeng-Jie Weng, Sheng-Xi Wu, He-San Luo, Ze-Sen Du, Xu-Yuan Li & Jia-Zhou Lin. (2021) Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response. INQUIRY: The Journal of Health Care Organization, Provision, and Financing 58, pages 004695802110562.
Crossref
Crossref
Daniele Marinelli, Marco Mazzotta, Laura Pizzuti, Eriseld Krasniqi, Teresa Gamucci, Clara Natoli, Antonino Grassadonia, Nicola Tinari, Silverio Tomao, Isabella Sperduti, Giuseppe Sanguineti, Andrea Botticelli, Agnese Fabbri, Claudio Botti, Gennaro Ciliberto, Maddalena Barba & Patrizia Vici. (2020) Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. Cancers 12:9, pages 2497.
Crossref
Crossref
Haiying Zhu, Chengyong Du, Meng Yuan, Peifen Fu, Qiaojun He, Bo Yang & Ji Cao. (2020) PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer. Drug Discovery Today 25:9, pages 1762-1771.
Crossref
Crossref